Volume 10, Number 5—May 2004
Mass Smallpox Vaccination and Cardiac Deaths, New York City, 1947
Highlight and copy the desired format.
|EID||Thorpe LE, Mostashari F, Karpati AM, Schwartz SP, Manning SE, Marx MA, et al. Mass Smallpox Vaccination and Cardiac Deaths, New York City, 1947. Emerg Infect Dis. 2004;10(5):917-920. https://dx.doi.org/10.3201/eid1005.040119|
|AMA||Thorpe LE, Mostashari F, Karpati AM, et al. Mass Smallpox Vaccination and Cardiac Deaths, New York City, 1947. Emerging Infectious Diseases. 2004;10(5):917-920. doi:10.3201/eid1005.040119.|
|APA||Thorpe, L. E., Mostashari, F., Karpati, A. M., Schwartz, S. P., Manning, S. E., Marx, M. A....Frieden, T. R. (2004). Mass Smallpox Vaccination and Cardiac Deaths, New York City, 1947. Emerging Infectious Diseases, 10(5), 917-920. https://dx.doi.org/10.3201/eid1005.040119.|
In April 1947, during a smallpox outbreak in New York City (NYC), >6,000,000 people were vaccinated. To determine whether vaccination increased cardiac death, we reviewed NYC death certificates for comparable periods in 1946 and 1948 (N = 81,529) and calculated adjusted relative death rates for the postvaccination period. No increases in cardiac deaths were observed.
Smallpox was successfully eradicated in 1980 after a global vaccination campaign by the World Health Organization. After the terrorist events of September and October 2001, the U.S. government initiated a campaign to immunize the American military and civilian first-responders in the event of an intentional release of the smallpox virus (1). From December through April 2003, smallpox vaccine was administered to 29,584 civilians and 365,000 military personnel nationwide (2,3). By March 28, four nonfatal and three fatal myocardial infarctions (MIs) had been reported. Whether these ischemic deaths were vaccine-associated or co-incidental is unclear.
To ascertain whether cardiac deaths increased after a large 1947 smallpox vaccination campaign in New York City (NYC), we examined death certificates from a 4-month period in 1947 as well as from comparable periods in 1946 and 1948. Key findings were published in an earlier article (4). We provide full results and additional methodologic detail here.
From April 4 through May 2, 1947, 6.35 million New Yorkers were vaccinated with the NYC Board of Health vaccinia strain (5). We used newspaper accounts and NYC Department of Health records to estimate the number of adults vaccinated on each of the 29 days (5). Since all of the 2003 cardiac events occurred from 4 to 17 days after vaccination, the 1947 vaccination numbers were divided equally across the same 14-day period to calculate the person-time at risk for potential cardiac death. On the basis of these estimates, we identified the 2- and 4-week “peak” risk periods in 1947.
We obtained all death certificates issued in NYC for the 4-month period between March and June, 1946–1948, from the NYC Municipal Archive. Cause of death was coded according to the International Classification of Diseases, 5th Revision (ICD-5) (6). We abstracted the date of death, age of decedent, and ICD-5–coded primary and other cause of death into an electronic database. We defined cause of death as “cardiac” if the ICD-5 codes for either cause included pericarditis (090), acute endocarditis (091), chronic endocarditis (092), myocardial disease (093), coronary artery diseases (094), and other disease of the heart (095).
We compared daily death rates during the postvaccination risk periods with rates at other times during the study period. We used Poisson regression, a generalized linear model appropriate for analysis of discrete data, to model counts of cardiac deaths (7). Counts were used instead of rates, as NYC’s population remained relatively constant during the study’s 3-year timeframe. We also adjusted for temporal trends in the data: a long-term trend from 1946 to 1948 (defined by weeks since January 1, 1946) and a seasonal trend between March and June (defined by days since March 1 for any given year). Secular trends were modeled with linear and quadratic terms. The main model included all cardiac deaths as the outcome variable and a dichotomous “exposure” variable indicating whether the death occurred during the 2-week risk period. Additional models examined subsets of cardiac disease and all-cause death as outcomes, as well as adjusting for noncardiac death volume.
An a priori power analysis found that the model had >90% power to detect a 5% increase in cardiac fatalities in the at-risk period. While this power would be more than sufficient to detect an excess of 2 deaths in 29,584 civilians (approximately 400 deaths in the 1947 NYC population of 6,000,000), it would not be able to detect very small elevations in risk.
At the height of the 1947 vaccination campaign, from April 17 to April 21, 500,000 to 1 million people were vaccinated daily (Figure 1). The 2-week at-risk period in 1947 was estimated to be April 22 to May 5, which encompassed 84% of the projected at-risk person-time for adverse cardiac complications. The 4-week period was identified as April 16 to May 13 and included 99% of the at-risk person-time.
During the months under review in 1946–1948, 81,529 death certificates were recorded, including 519 (0.6%) records with an illegible cause of death. Of the remaining 81,010 records, 48% had heart disease listed as a cause of death. A total of 9,112 (11%) specifically referred to coronary artery or atherosclerotic disease. The number of daily deaths from heart disease in the months of March to June of 1946, 1947, and 1948 ranged from 72 to 149, with an increasing long-term trend and decreasing seasonal trend (Figure 2). In the 2-week estimated risk period in 1947, 1,545 cardiac deaths occurred of 3,156 total deaths (average 110 deaths per day, range 91–119 deaths) (Table 1).
In the main regression model (Table 2), no independent association was found between cardiac deaths and the 2-week estimated risk period. The findings remained nonsignificant when the model was restricted to those 50 to 64 years of age and when adjustments for noncardiac deaths were made (rate ratio 1.01; 95% confidence interval 0.95 to 1.06). Additional analyses examining different outcomes (all deaths, atherosclerotic deaths, or deaths due to myopericarditis) did not show any significant increase in deaths, nor did expanding the estimated risk period to 4 weeks.
Our analysis found no significant increase in reported cardiac deaths after the 1947 mass smallpox vaccination campaign in NYC. The campaign was unique in terms of the number of people vaccinated in one area in a short period. The high intensity and coverage of the vaccination campaign permitted a focused cardiac death assessment.
Recent reports of cardiac deaths after smallpox vaccination have raised concerns regarding the safety of the current vaccination initiative. The NYC Board of Health vaccinia strain used today is the same as was used in 1947 (5). As described in our prior publication (4), vaccinia is a DNA virus with limited antigenic variability (8), and antigenic shifts are unlikely. Regarding the vaccinated population, major risk factors, such as smoking and hypertension, were more widespread in 1947 than they are at present (9–11), and the death rate due to heart disease was nearly three times higher (11). If, as the 2003 cardiac fatalities suggest, cardiac risk factors increase vaccine-associated death rates, we should have seen an even-greater cardiac mortality risk in 1947.
Our analysis has some limitations. First, this analysis was ecologic, and we had no information on the vaccination status of decedents. More than 80% of the NYC population was vaccinated within the 4-week period, however, which minimizes the risk of faulty ecologic inference. The campaign urged all New Yorkers to get vaccinated, irrespective of age, health, or pregnancy (5), and the likelihood of systematic bias that would mask an association is small.
Second, death certificate information may have been incomplete or inaccurate. We extracted ICD codes for >99% of hardcopy death certificates, and missed codes were unlikely to affect the findings of the study. We also have no reason to believe that cardiac deaths were systematically misclassified in the peak risk exposure period as compared with other times. ICD-5 heart disease codes and later ICD revisions have been assessed to have a high comparability ratio, from 0.98 to 1.01 (6).
Third, assumptions pertaining to a Poisson distribution may not be appropriate for these cardiac death data (11). However, no biologically plausible concern existed for underdispersion, and goodness-of-fit statistics suggested adequate fit. Null findings of the study reduce concern for overdispersion, which could have otherwise potentially caused us to report an association that was not causal.
Finally, although the survey had substantial statistical power to detect small increases in cardiac deaths in the estimated at-risk period, extremely small increases may not have been detectable. In a large population, even small elevations in risk will produce a sizable absolute number of deaths. In light of this limitation, common to all observational studies, these findings should be interpreted in the context of other study findings.
Any one study will not likely be able to definitively rule out a causal relationship between cardiac deaths among recent vaccinees and the vaccine itself, but findings from our study provide some reassurance that the current smallpox vaccination program is unlikely to increase risk for death from coronary disease. In 1947, the commissioner of health of NYC reminded his peers, “Whenever a large-scale vaccination program is undertaken, there is always the possibility that there may be some unfortunate complications…. In New York City, there are thousands of people who become ill, and about two hundred of them die every day. Since practically every person in New York City had a recent vaccination, it was inevitable that some of them would become ill and would die. Vaccination does not stop the normal course of events. Neither should vaccination be blamed for a death from cerebral hemorrhage, nephritis, or coronary occlusion (5).”
We thank the many staff members at the New York City Department of Health and Mental Hygiene (NYC DOMH) who worked long hours to rapidly enter these data, as well as the staff of the NYC DOHMH Public Health Library (particularly Kristine Alpi, and Tamantha Smith), MIS (Julian Yuen, Anita Ho, Ron Dylan), Vital Records (Richard Genevese), Denis Nash, and the Smallpox Vaccination and Adverse Events Team. We also thank Starros Memtsoudis; Martin Kulldorf for his advice and assistance with statistical matters; Robert Chen, Susan Chu, Michael Lane, John Livengood, Linda Neff, Walter Orenstein, Richard Schreiber, Donna Stroup, Stephanie Zaza, and the Cardiac Investigation Task Force of the National immunization Program for their comments and technical assistance; and Barbara S. Chang for suggesting the analysis.
- Smallpox overview [monograph on the Internet]. Atlanta: Centers for Disease Control and Prevention; 2002 Dec 9 [cited 2003 Aug 21]. Available from: http://www.bt.cdc.gov/agent/smallpox/overview/disease-facts.asp
- Cardiac adverse events following smallpox vaccination—United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:248–50.
- Update: adverse events following smallpox vaccination—United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:278–82.
- Cardiac deaths after a mass smallpox vaccination campaign—New York City, 1947. MMWR Morb Mortal Wkly Rep. 2003;52:933–6.
- Weinstein I. An outbreak of smallpox in New York City. Am J Public Health. 1947;37:1347–84.
- International classification of diseases (ICD) revision number and dates in use: Comparability across revisions for selected causes [monograph on the Internet]. Bethesda (MD): National Center for Health Statistics; 2003 [cited 2003 Apr 10]. Available from: http://www.cdc.gov/nchs/data/statab/comp2.pdf
- Armitage P, Berry G. Statistical methods in medical research. 3rd ed. London: Blackwell; 1994.
- Lane JM. Smallpox vaccine [presentation on the Internet]. Atlanta: Centers for Disease Control and Prevention; 2003 [cited 2003 Apr 10]. Available from: http://www.bt.cdc.gov/agent/smallpox/training/aeworkshop/smallpox-vaccine.pdf
- Creek L, Capehart T, Grise VUS. Tobacco Statistics, 1935–92. Statistical Bulletin No. 869. Washington: U.S. Dept. of Agriculture, Economic Research Service, Commodity Economics Division; 1994.
- Reducing tobacco use: a report from the Surgeon General. Atlanta: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2000.
- Bengtsson E, Lundstrom R. Postvaccinial myocarditis. Cardiologia. 1957;30:1–8.
- Figure 1. Adult vaccination doses administered and estimated person-time at risk for fatal cardiac adverse effects, New York City, 1947.
- Figure 2. Daily deaths from cardiac causes, New York City, March to June, 1946–1948.
- Table 1. Death counts by cause of death and postvaccination exposure period
- Table 2. Rate ratio (RR) and 95% confidence interval (CI) of cardiac death rates comparing postvaccination to reference periods,a New York City, March–June, 1946–1948
1At the time of this study, Dr. Karpati was jointly affiliated with the New York City Department of Health and Mental Hygiene and the Centers for Disease Control and Prevention.
Please use the form below to submit correspondence to the authors or contact them at the following address:
Lorna E. Thorpe, NYC DOHMH, 125 Worth St. Rm. 315 (CN6), New York, NY 10013, USA; fax: 212-788-4473
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: February 22, 2011
- Page last updated: February 22, 2011
- Page last reviewed: February 22, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)